Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives

Obstetrics and Gynecology

Volumn 79, Issue 4, 1992, Pages 529-533

  Holt, Victoria L ^a,b,c   Daling, Janet R ^a,b,c   McKnight, Barbara ^a,b,c   Moore, Don ^a,b,c   Stergachis, Andy ^a,b,c   Weiss, Noel S ^a,b,c  

^a FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; MESTRANOL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY CYST; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMAN; OVARIAN CYSTS; REGRESSION ANALYSIS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0026518869     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Grimes DA, Hughes JM. Use of multiphasic oral contraceptives and hospitalizations of women with functional ovarian cysts in the United States. Obstet Gynecol 1989;73:1037-9.
2. Ramcharan S, Pellegrin FA, Ray R, Hsu J-P. The Walnut Creek Contraceptive Drug Study. Vol III. Bethesda, Maryland: Center for Population Research, National Institute of Child Health and Human Development, United States Department of Health and Human Services, 1981.
3. Royal College of General Practitioners. Oral contraceptives and health. Tunbridge Wells, Kent, England: Pitman Medical Publishing, 1974.
4. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 1987;294:1518-20.
5. Ory H. Functional ovarian cysts and oral contraceptives. JAMA 1974;228:68-9.
6. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985;92:1003-9.
7. Caillouette JC, Koehler AL. Phasic contraceptive pills and functional ovarian cysts. Am J Obstet Gynecol 1987;156:1538-42.
8. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
9. Jick H, Walker AM, Watkins RN, et al. Oral contraceptives and breast cancer. Am J Epidemiol 1980;112:577-85.
10. Jick H, Watkins RN, Hunter JR, et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979;300:218-22.
11. Breslow NE, Day ND. Statistical methods in cancer research. Vol 1. The analysis of case control studies. Lyon, France: International Agency for Research on Cancer, 1980.
12. Spellacy WN, Kalra PS, Buhi WC, Birk SA. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive. Am J Obstet Gynecol 1980;137:109-15.
13. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. Br Med J 1980;280:1157-61.
14. Chowdhury V, Joshi UM, Gopalkrishna K, Betrabet S, Mehta S, Saxena BN. “Escape” ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception 1980;22:241-7.